HeartSciences Revenue 2022-2025 | HSCS
HeartSciences revenue from 2022 to 2025. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
| HeartSciences Annual Revenue (Millions of US $) |
|
|---|---|
| 2024 | $0 |
| 2023 | $0 |
| 2022 | $0 |
| 2021 | $0 |
| HeartSciences Quarterly Revenue (Millions of US $) |
|
|---|---|
| 2025-01-31 | |
| 2024-10-31 | |
| 2024-07-31 | |
| 2024-04-30 | |
| 2024-01-31 | $0 |
| 2023-10-31 | $0 |
| 2023-07-31 | |
| 2023-04-30 | $0 |
| 2023-01-31 | $0 |
| 2022-10-31 | |
| 2022-07-31 | $0 |
| 2022-04-30 | $0 |
| 2022-01-31 | $0 |
| 2021-10-31 | |
| 2021-07-31 | $0 |
| 2021-04-30 | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Information Systems | $0.004B | $0.000B |
| Heart Test Laboratories, Inc. d/b/a HeartSciences is a medical technology company focused on applying innovative AI-based technology to an ECG (also known as an EKG) to expand and improve an ECG's clinical utility. Millions of ECGs are performed every week and the Company's objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. HeartSciences has one of the largest libraries of AI-ECG algorithms and is developing AI-ECG solutions to be made available on either a hardware agnostic cloud-based platform or its proprietary MyoVista? wavECG(TM) device, to help identify cardiovascular disease in any care setting worldwide in a manner to best suit different care providers. HeartSciences' first product candidate for FDA clearance, the MyoVista? wavECG(TM), or the MyoVista(R), is a resting 12-lead ECG that is also designed to provide diagnostic information related to cardiac dysfunction. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Veeva Systems (VEEV) | United States | $39.499B | 54.56 |
| Hims & Hers Health (HIMS) | United States | $14.471B | 150.35 |
| Tempus AI (TEM) | United States | $11.278B | 0.00 |
| Inspire Medical Systems (INSP) | United States | $4.503B | 70.36 |
| IRhythm Technologies (IRTC) | United States | $4.501B | 0.00 |
| Privia Health (PRVA) | United States | $3.050B | 208.50 |
| Enovis (ENOV) | United States | $2.060B | 11.48 |
| Clover Health Investments (CLOV) | United States | $1.807B | 0.00 |
| Schrodinger (SDGR) | United States | $1.722B | 0.00 |
| Phreesia (PHR) | United States | $1.510B | 0.00 |
| Omnicell (OMCL) | United States | $1.310B | 23.11 |
| Azenta (AZTA) | United States | $1.258B | 58.45 |
| 10x Genomics (TXG) | United States | $1.156B | 0.00 |
| Fulgent Genetics (FLGT) | United States | $0.620B | 0.00 |
| Butterfly Network (BFLY) | United States | $0.581B | 0.00 |
| Talkspace (TALK) | United States | $0.499B | 149.00 |
| Veradigm (MDRX) | United States | $0.455B | 0.00 |
| Claritev (CTEV) | United States | $0.450B | 0.00 |
| Standard BioTools (LAB) | United States | $0.410B | 0.00 |
| TruBridge (TBRG) | United States | $0.376B | 834.67 |
| Health Catalyst (HCAT) | United States | $0.283B | 0.00 |
| Nyxoah SA (NYXH) | Belgium | $0.214B | 0.00 |
| SOPHiA GENETICS SA (SOPH) | Switzerland | $0.197B | 0.00 |
| EUDA Health Holdings (EUDA) | Singapore | $0.142B | 0.00 |
| Pulmonx (LUNG) | United States | $0.138B | 0.00 |
| American Well (AMWL) | United States | $0.116B | 0.00 |
| MDxHealth SA (MDXH) | Belgium | $0.099B | 0.00 |
| CareCloud (CCLD) | United States | $0.089B | 3.39 |
| Outset Medical (OM) | United States | $0.070B | 0.00 |
| 111 (YI) | China | $0.068B | 0.00 |
| Retrieve Medical Holdings (RMHI) | United States | $0.059B | 0.00 |
| P3 Health Partners (PIII) | United States | $0.057B | 0.00 |
| HeartBeam (BEAT) | United States | $0.052B | 0.00 |
| Zepp Health (ZEPP) | Netherlands | $0.040B | 0.00 |
| Zhongchao (ZCMD) | China | $0.032B | 0.00 |
| ImmunoPrecise Antibodies (IPA) | Canada | $0.023B | 0.00 |
| Bullfrog AI Holdings (BFRG) | United States | $0.016B | 0.00 |
| MSP Recovery (MSPR) | United States | $0.013B | 0.00 |
| Precipio (PRPO) | United States | $0.012B | 0.00 |
| Strata Skin Sciences (SSKN) | United States | $0.011B | 0.00 |
| Predictive Oncology (POAI) | United States | $0.010B | 0.00 |
| Streamline Health Solutions (STRM) | United States | $0.010B | 0.00 |
| Movano (MOVE) | United States | $0.007B | 0.00 |
| Mobile-health Network Solutions (MNDR) | Singapore | $0.004B | 0.00 |
| Tivic Health Systems (TIVC) | United States | $0.004B | 0.00 |
| Healthcare Triangle (HCTI) | United States | $0.000B | 0.00 |
| Future Health ESG (FHLT) | United States | $0.000B | 0.00 |